NCT02897297 Myeloproliferative Neoplastic Diseases Observatory From Brest
| NCT ID | NCT02897297 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Polycythemia Vera |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2015-09-01 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2015-09-01 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
All patients diagnosed or followed in Brest University Hospital for Philadelphia negative myeloproliferative neoplasms will be included in this observational study. Myeloproliferative neoplasms recorded included: polycythemia vera, essential Thrombocythemia and Primary Myelofibrosis. This is a not interventional study. Alive patients need to sign a non-opposition consent form. Patients will be followed until last news (death, change of reference centre...).
Eligibility Criteria
Inclusion Criteria: * Patients with essentiel thrombocythemia, polycythemia vera or primary myelofibrosis * Signature of the non-opposition consent form Exclusion Criteria: * None
Contact & Investigator
Jean-Christophe Ianotto
✉ jean-christophe.Ianotto@chu-brest.frJean-Christophe Ianotto
STUDY DIRECTOR
CHRU de Brest
Frequently Asked Questions
Who can join the NCT02897297 clinical trial?
This trial is open to participants of all sexes, studying Polycythemia Vera. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02897297 currently recruiting?
Yes, NCT02897297 is actively recruiting participants. Contact the research team at jean-christophe.Ianotto@chu-brest.fr for enrollment information.
Where is the NCT02897297 trial being conducted?
This trial is being conducted at Brest, France.
Who is sponsoring the NCT02897297 clinical trial?
NCT02897297 is sponsored by University Hospital, Brest. The principal investigator is Jean-Christophe Ianotto at CHRU de Brest. The trial plans to enroll 1,000 participants.